Skip to main navigation Skip to search Skip to main content

Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review

  • Julia Schroer
  • , Paul Jan Bröckelmann
  • , Sam Salek
  • , Tatyana Ionova
  • , Edward Laane
  • , Esther Natalie Oliva
  • , Ina Monsef
  • , Nicole Skoetz
  • , Mario Csenar

Research output: Contribution to journal › Review article › peer-review

2 Downloads (Pure)

Abstract

Background: Non-Hodgkin lymphoma (NHL) constitutes a biologically and clinically heterogeneous group of lymphoid malignancies, with varying prognoses and treatment aims between indolent and aggressive subtypes. While survival outcomes remain key efficacy measures, they insufficiently capture the impact of disease and treatment on daily physical and psychosocial functioning, as well as quality of life (QoL). Objectives: To characterize the use and reporting of patient-reported outcomes (PROs) in adult NHL randomized controlled trials (RCTs), including the trajectory of PRO dissemination throughout the trial reporting process. Methods: MEDLINE, CENTRAL, ClinicalTrials.gov, and WHO ICTRP were systematically searched from 1 January 2017 to 19 January 2023 for NHL RCTs irrespective of subtype, with databases being re-searched until 4 February 2025. Cross-sectional and longitudinal descriptive analyses were conducted to investigate PRO use and reporting practices. Findings: 549 completed and ongoing RCTs met the eligibility criteria, of which 176 trials (32.1%) included a reference to PROs, and 27 (4.9%) used a PRO as a primary outcome. Overall, 95 PRO measures were identified across trials, with EORTC QLQ-C30, FACT-Lymphoma, and EQ-5D being referenced most frequently. Among trials with published results that pre-specified PROs, 25.0% entirely and 10.5% partly omitted PRO findings from their main full-texts, without addressing this shortcoming in subsequent publications. Conclusion: PROs are underused and underreported in RCTs in NHL. Standardized PRO evaluation methodology and guidance for the selection of fit-for-purpose PRO measures are needed, along with clear positioning of PROs alongside survival outcomes in clinical trial design and interpretation.
Original languageEnglish
Article number31
Number of pages13
JournalJournal of Patient-Reported Outcomes
Volume10
Issue number1
Early online date28 Jan 2026
DOIs
Publication statusE-pub ahead of print - 28 Jan 2026

Keywords

  • Non-Hodgkin lymphoma
  • Quality of life
  • PRO instrument
  • Patient-reported experience
  • Sankey diagram
  • Patient-reported outcomes
  • Scoping review

Fingerprint

Dive into the research topics of 'Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review'. Together they form a unique fingerprint.

Cite this